Literature DB >> 24167038

PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity.

Graziella Madeo1, Tommaso Schirinzi, Giuseppina Martella, E Claudio Latagliata, Francesca Puglisi, Jie Shen, Enza Maria Valente, Mauro Federici, Nicola B Mercuri, Stefano Puglisi-Allegra, Paola Bonsi, Antonio Pisani.   

Abstract

Homozygous or compound heterozygous mutations in the phosphatase and tensin homolog-induced putative kinase 1 (PINK1) gene are causative of autosomal recessive, early onset Parkinson's disease. Single heterozygous mutations have been detected repeatedly both in a subset of patients and in unaffected individuals, and the significance of these mutations has long been debated. Several neurophysiological studies from non-manifesting PINK1 heterozygotes have demonstrated the existence of neural plasticity abnormalities, indicating the presence of specific endophenotypic traits in the heterozygous state. We performed a functional analysis of corticostriatal synaptic plasticity in heterozygous PINK1 knockout (PINK1(+/-) ) mice using a multidisciplinary approach and observed that, despite normal motor behavior, repetitive activation of cortical inputs to striatal neurons failed to induce long-term potentiation (LTP), whereas long-term depression was normal. Although nigral dopaminergic neurons exhibited normal morphological and electrophysiological properties with normal responses to dopamine receptor activation, a significantly lower dopamine release was measured in the striatum of PINK1(+/-) mice compared with control mice, suggesting that a decrease in stimulus-evoked dopamine overflow acts as a major determinant for the LTP deficit. Accordingly, pharmacological agents capable of increasing the availability of dopamine in the synaptic cleft restored normal LTP in heterozygous mice. Moreover, monoamine oxidase B inhibitors rescued physiological LTP and normal dopamine release. Our results provide novel evidence for striatal plasticity abnormalities, even in the heterozygous disease state. These alterations might be considered an endophenotype to this monogenic form of Parkinson's disease and a valid tool with which to characterize early disease stage and design possible disease-modifying therapies.
Copyright © 2013 Movement Disorder Society.

Entities:  

Keywords:  PINK1; autosomal recessive Parkinson's disease; heterozygous mutations; striatum; synaptic plasticity

Mesh:

Substances:

Year:  2013        PMID: 24167038      PMCID: PMC4022284          DOI: 10.1002/mds.25724

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  70 in total

Review 1.  Monoamine oxidase B inhibitors for the treatment of Parkinson's disease: a review of symptomatic and potential disease-modifying effects.

Authors:  Anthony H V Schapira
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb.

Authors:  Lisa Glasl; Karina Kloos; Florian Giesert; Anne Roethig; Barbara Di Benedetto; Ralf Kühn; Jingzhong Zhang; Ulrich Hafen; Julia Zerle; Andreas Hofmann; Martin Hrabé de Angelis; Konstanze F Winklhofer; Sabine M Hölter; Daniela M Vogt Weisenhorn; Wolfgang Wurst
Journal:  Exp Neurol       Date:  2012-01-11       Impact factor: 5.330

Review 3.  Parkinson's disease: pathophysiology.

Authors:  Y Agid
Journal:  Lancet       Date:  1991-06-01       Impact factor: 79.321

4.  The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson's disease.

Authors:  Alessandro Tozzi; Antonio de Iure; Massimiliano Di Filippo; Michela Tantucci; Cinzia Costa; Franco Borsini; Veronica Ghiglieri; Carmen Giampà; Francesca Romana Fusco; Barbara Picconi; Paolo Calabresi
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

5.  Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1.

Authors:  Matthew S Goldberg; Antonio Pisani; Marian Haburcak; Timothy A Vortherms; Tohru Kitada; Cinzia Costa; Youren Tong; Giuseppina Martella; Anne Tscherter; Andrea Martins; Giorgio Bernardi; Bryan L Roth; Emmanuel N Pothos; Paolo Calabresi; Jie Shen
Journal:  Neuron       Date:  2005-02-17       Impact factor: 17.173

Review 6.  Synuclein deposition and non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neurol Sci       Date:  2011-05-12       Impact factor: 3.181

Review 7.  Parkinson's disease: mechanisms and models.

Authors:  William Dauer; Serge Przedborski
Journal:  Neuron       Date:  2003-09-11       Impact factor: 17.173

8.  Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine.

Authors:  Giuseppina Martella; Annalisa Tassone; Giuseppe Sciamanna; Paola Platania; Dario Cuomo; Maria Teresa Viscomi; Paola Bonsi; Emanuele Cacci; Stefano Biagioni; Alessandro Usiello; Giorgio Bernardi; Nutan Sharma; David G Standaert; Antonio Pisani
Journal:  Brain       Date:  2009-07-29       Impact factor: 13.501

Review 9.  Deciphering the role of heterozygous mutations in genes associated with parkinsonism.

Authors:  Christine Klein; Katja Lohmann-Hedrich; Ekaterina Rogaeva; Michael G Schlossmacher; Anthony E Lang
Journal:  Lancet Neurol       Date:  2007-07       Impact factor: 44.182

10.  Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.

Authors:  Naheed L Khan; David J Brooks; Nicola Pavese; Mary G Sweeney; Nicholas W Wood; Andrew J Lees; Paola Piccini
Journal:  Brain       Date:  2002-10       Impact factor: 13.501

View more
  14 in total

1.  PINK1 Silencing Modifies Dendritic Spine Dynamics of Mouse Hippocampal Neurons.

Authors:  C J Hernández; C Báez-Becerra; M J Contreras-Zárate; H Arboleda; G Arboleda
Journal:  J Mol Neurosci       Date:  2019-09-05       Impact factor: 3.444

2.  Loss of Pink1 modulates synaptic mitochondrial bioenergetics in the rat striatum prior to motor symptoms: concomitant complex I respiratory defects and increased complex II-mediated respiration.

Authors:  Kelly L Stauch; Lance M Villeneuve; Phillip R Purnell; Brendan M Ottemann; Katy Emanuel; Howard S Fox
Journal:  Proteomics Clin Appl       Date:  2016-09-21       Impact factor: 3.494

Review 3.  Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.

Authors:  Michael J Beckstead; Rebecca D Howell
Journal:  Exp Neurol       Date:  2021-03-20       Impact factor: 5.620

4.  Double hit mouse model of Parkinson's disease.

Authors:  Tommaso Schirinzi; Giuseppina Martella; Antonio Pisani
Journal:  Oncotarget       Date:  2016-12-06

5.  Changes in functional organization and white matter integrity in the connectome in Parkinson's disease.

Authors:  Sule Tinaz; Peter M Lauro; Pritha Ghosh; Codrin Lungu; Silvina G Horovitz
Journal:  Neuroimage Clin       Date:  2016-12-19       Impact factor: 4.881

6.  Synaptic Plasticity Changes: Hallmark for Neurological and Psychiatric Disorders.

Authors:  Giuseppina Martella; Paola Bonsi; Steven W Johnson; Angelo Quartarone
Journal:  Neural Plast       Date:  2018-10-23       Impact factor: 3.599

Review 7.  Spiny Projection Neuron Dynamics in Toxin and Transgenic Models of Parkinson's Disease.

Authors:  Yijuan Du; Steven M Graves
Journal:  Front Neural Circuits       Date:  2019-03-15       Impact factor: 3.492

8.  Increased glutamate transmission onto dorsal striatum spiny projection neurons in Pink1 knockout rats.

Authors:  Rose B Creed; Rosalinda C Roberts; Charlene B Farmer; Lori L McMahon; Matthew S Goldberg
Journal:  Neurobiol Dis       Date:  2020-12-30       Impact factor: 5.996

9.  Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation.

Authors:  Sylvia Torres-Odio; Jana Key; Hans-Hermann Hoepken; Júlia Canet-Pons; Lucie Valek; Bastian Roller; Michael Walter; Blas Morales-Gordo; David Meierhofer; Patrick N Harter; Michel Mittelbronn; Irmgard Tegeder; Suzana Gispert; Georg Auburger
Journal:  J Neuroinflammation       Date:  2017-08-02       Impact factor: 8.322

Review 10.  Centrality of Early Synaptopathy in Parkinson's Disease.

Authors:  Paola Imbriani; Tommaso Schirinzi; Maria Meringolo; Nicola B Mercuri; Antonio Pisani
Journal:  Front Neurol       Date:  2018-03-01       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.